HSP27 inhibitor J2 (Synonyms: J2) |
| Catalog No.GC38503 |
HSP27 inhibitor J2 (J2) is an inhibitor of HSP27, which significantly induces abnormal HSP27 dimer formation and inhibits HSP27 macropolymer production.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2133499-85-9
Sample solution is provided at 25 µL, 10mM.
HSP27 inhibitor J2 (J2) is an inhibitor of HSP27, which significantly induces abnormal HSP27 dimer formation and inhibits HSP27 macropolymer production[1-3].
J2(10 µM J2;12 hr)showed stronger HSP27 cross linking activity in HSP27 high expressed lung cancer cells and relatively low cytoxicity[4].
J2(15 mg/kg; i.p; on every other day after irradiation for 14d) treatment significantly inhibited immune cell infiltration in lung tissue. J2-treated mice reversed radiation-induced respiratory distress. J2 inhibited IR-induced lung fibrosis in mice[5-6].
References:
[1]. Hwang SY, Kwak SY, et,al. Synthesis and biological effect of chrom-4-one derivatives as functional inhibitors of heat shock protein 27. Eur J Med Chem. 2017 Oct 20;139:892-900. doi: 10.1016/j.ejmech.2017.08.065. Epub 2017 Sep 1. PMID: 28869891.
[2]. Garrido C, Bruey JM, et,al. HSP27 inhibits cytochrome c-dependent activation of procaspase-9. FASEB J. 1999 Nov;13(14):2061-70. doi: 10.1096/fasebj.13.14.2061. PMID: 10544189.
[3]. Younghwa Na, et al. Methods for treating pulmonary fibrosis using chromenone derivatives.
[4]. Choi B, Choi SK, et,al. Sensitization of lung cancer cells by altered dimerization of HSP27. Oncotarget. 2017 Oct 31;8(62):105372-105382. doi: 10.18632/oncotarget.22192. PMID: 29285257; PMCID: PMC5739644.
[5]. Kim JY, An YM, et,al. HSP27 inhibitor attenuates radiation-induced pulmonary inflammation. Sci Rep. 2018 Mar 8;8(1):4189. doi: 10.1038/s41598-018-22635-9. PMID: 29520071; PMCID: PMC5843649.
[6]. Kim JY, Jeon S, et,al. The Hsp27-Mediated IkBα-NFκB Signaling Axis Promotes Radiation-Induced Lung Fibrosis. Clin Cancer Res. 2019 Sep 1;25(17):5364-5375. doi: 10.1158/1078-0432.CCR-18-3900. Epub 2019 May 24. PMID: 31126962.
| Cell experiment [1]: | |
|
Cell lines |
NCI-H460 cells |
|
Preparation Method |
Cells were treated with J2 at 10 µM for 12 hr. |
|
Reaction Conditions |
10 µM J2;12 hr |
|
Applications |
J2 showed stronger HSP27 cross linking activity in HSP27 high expressed lung cancer cells. |
| Animal experiment [2]: | |
|
Animal models |
Male C57BL/6 mice |
|
Preparation Method |
Mice were exposed to a single dose of 75 Gy delivered to the left lung in a single fraction,15 mg/kg of J2 was intraperitoneal administered on every other day after irradiation. |
|
Dosage form |
15 mg/kg; i.p; every other day after irradiation for 14d. |
|
Applications |
J2 treatment significantly inhibited immune cell infiltration in lung tissue. |
|
References: [1]. Choi B, Choi SK, et,al. Sensitization of lung cancer cells by altered dimerization of HSP27. Oncotarget. 2017 Oct 31;8(62):105372-105382. doi: 10.18632/oncotarget.22192. PMID: 29285257; PMCID: PMC5739644. |
|
| Cas No. | 2133499-85-9 | SDF | |
| Synonyms | J2 | ||
| Canonical SMILES | O=C1C=C(C)OC2=C1C(O)=CC(OCC3SC3)=C2 | ||
| Formula | C13H12O4S | M.Wt | 264.3 |
| Solubility | DMSO: 25 mg/mL (94.59 mM) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.7836 mL | 18.9179 mL | 37.8358 mL |
| 5 mM | 0.7567 mL | 3.7836 mL | 7.5672 mL |
| 10 mM | 0.3784 mL | 1.8918 mL | 3.7836 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 24 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *